| Stereochemistry | ACHIRAL |
| Molecular Formula | C19H20N2O2S |
| Molecular Weight | 340.439 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC1=C(N)C=CC=C1CN2C=CC(OCCC3=CC=CS3)=CC2=O
InChI
InChIKey=YCLREGRRHGLOAK-UHFFFAOYSA-N
InChI=1S/C19H20N2O2S/c1-14-15(4-2-6-18(14)20)13-21-9-7-16(12-19(21)22)23-10-8-17-5-3-11-24-17/h2-7,9,11-12H,8,10,13,20H2,1H3
| Molecular Formula | C19H20N2O2S |
| Molecular Weight | 340.439 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
CG-400549, also known as CG-0549, is an enoyl-(acyl-carrier protein) reductase fabl inhibitor developed by CrystalGenomics for the treatment of compcolicated acute and methicillin-resistant Staphylococcus aureus. CG400549 shows potent antimicrobial activity against 203 S. aureus strains and was more potent than either linezolid or vancomycin. An animal study showed that CG-400549has potential for the treatment of staphylococcal infections in mice and rats
Approval Year
PubMed
Patents
Showing 1 to 1 of 1 entries
